Recently, a double-blind, phase III trial, randomly assigned 616 NSCLC patients with metastatic non-squamous NSCLC without EGFR and ALK mutations who were chemotherapy-naïve to receive pemetrexed and a platinum-based drug plus either placebo or pembrolizumab [284]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.